Astrocytoma, Grade III
15
4
5
7
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
13.3%
2 terminated out of 15 trials
77.8%
-8.7% vs benchmark
0%
0 trials in Phase 3/4
71%
5 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (15)
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma
Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.
A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
Study of Olutasidenib and Temozolomide in HGG
Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine
Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas
Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma